Search hospitals > Pennsylvania > Harrisburg
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Claim this profileHarrisburg, Pennsylvania 17109
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
90 reported clinical trials
22 medical researchers
Summary
UPMC Pinnacle Cancer Center/Community Osteopathic Campus is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. UPMC Pinnacle Cancer Center/Community Osteopathic Campus is involved with conducting 90 clinical trials across 136 conditions. There are 22 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
37 reported clinical trials
53 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
18 reported clinical trials
33 drugs studied
Anuradha KrishnamurthyUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
32 drugs studied
Clinical Trials running at UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Cancer
Oropharyngeal Carcinoma
Small Cell Lung Cancer
Laryngeal Cancer
Prostate Adenocarcinoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Sacituzumab Govitecan
for Brain Metastases from Breast Cancer
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
Recruiting1 award Phase 212 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UPMC Pinnacle Cancer Center/Community Osteopathic Campus?
UPMC Pinnacle Cancer Center/Community Osteopathic Campus is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. UPMC Pinnacle Cancer Center/Community Osteopathic Campus is involved with conducting 90 clinical trials across 136 conditions. There are 22 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.